 |
PDBsum entry 1h00
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
References listed in PDB file
|
|
|
Key reference
|
|
|
Title
|
|
Cyclin-Dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-Bis anilino pyrimidines.
|
|
|
Authors
|
|
J.F.Beattie,
G.A.Breault,
R.P.Ellston,
S.Green,
P.J.Jewsbury,
C.J.Midgley,
R.T.Naven,
C.A.Minshull,
R.A.Pauptit,
J.A.Tucker,
J.E.Pease.
|
|
|
Ref.
|
|
Bioorg Med Chem Lett, 2003,
13,
2955-2960.
[DOI no: ]
|
|
|
PubMed id
|
|
|
|
|
|
Abstract
|
|
|
Using a high-throughput screening campaign, we identified the 4,6-bis anilino
pyrimidines as inhibitors of the cyclin-dependent kinase, CDK4. Herein we
describe the further chemical modification and use of X-ray crystallography to
develop potent and selective in vitro inhibitors of CDK4.
|
|
|
Secondary reference #1
|
|
|
Title
|
|
High-Resolution crystal structures of human cyclin-Dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design.
|
|
|
Authors
|
|
U.Schulze-Gahmen,
H.L.De bondt,
S.H.Kim.
|
|
|
Ref.
|
|
J Med Chem, 1996,
39,
4540-4546.
[DOI no: ]
|
|
|
PubMed id
|
|
|
|
|
|
|
|
|
|
|
|
|
